Workflow
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Core Insights - Vigil Neuroscience is advancing its clinical programs, with key milestones expected in 2025, including the final analysis of iluzanebart in ALSP and the initiation of a Phase 2 trial for VG-3927 in Alzheimer's disease [1][2][3] Clinical Development Updates - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is scheduled for Q2 2025, with plans for an accelerated approval pathway in ALSP [3] - VG-3927 has shown positive Phase 1 data, supporting the initiation of a Phase 2 trial in Q3 2025 for Alzheimer's disease [2][4] - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and significant pharmacokinetic and pharmacodynamic results [4] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities of $87.1 million, down from $97.8 million at the end of 2024, with expectations to fund operations into 2026 [9][13] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher costs in preclinical and manufacturing activities [9][11] - The net loss for Q1 2025 was $22.4 million, compared to $19.9 million for the same period in 2024, with a net loss per share of $0.49 [9][11]